In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. HealthDay News — ...

For instance, in February 2024, Roche announced that the US Food and Drug Administration (FDA) approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a ...

Planning ahead is the best medicine for a quick and healthy recovery from surgery. Learn about the causes and best treatment options for hair loss. Learn the presurgery tips that can help improve ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

The FDA has approved Susvimo, which delivers medicine continuously via a surgical implant that can be refilled every six months vs. getting monthly injections. For those with diabetic macular edema ...

A look at the current state of AI in diabetic eye disease and where the future may take us. Artificial intelligence (AI) and deep learning tools are now a part of many people’s daily lives, whether ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...